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Abstract
Background: The highest Hepatitis C Virus (HCV) prevalence in the world occurs in Egypt. Several studies from
different parts of the world have found that 13% to 33% of patients with chronic HCV have associated diabetes,
mostly type II Diabetes Mellitus (DM). In Egypt the prevalence of DM is 25.4% among HCV patients. Therefore, it is
important to identify the magnitude of the problem of diabetes in order to optimize the treatment of chronic
hepatitis C.
Methods: The objective of this case-control study was to evaluate the prevalence of DM and other extrahepatic
(EH) manifestations among patients with different HCV morbidity stages including asymptomatic, chronic hepatic
and cirrhotic patients. In this study, 289 HCV patients older than 18 were selected as cases. Also, 289 healthy
controls were included. Laboratory investigations including Liver Function tests (LFT) and blood glucose level were
done. Also serological assays including cryoglobulin profile, rheumatoid factor, antinuclear antibody, HCV-PCR were
performed.
Results: Out of 289 HCV cases, 40 (13.84%) were diabetic. Out of 289 healthy controls, 12 (4.15%) were diabetic. It
was found that the diabetic HCV group mean age was [48.1 (± 9.2)]. Males and urbanians represented 72.5% and
85% respectively. Lower level of education was manifested in 52.5% and 87.5% were married. In the nondiabetic
HCV group mean age was [40.7 (± 10.4)]. Males and urbanians represented 71.5% and 655% respectively. secondary
and higher level of education was attained in 55.4% and 76.7% were married. Comparing between the diabetic
HCV group and the non diabetic HCV group, age, residence and alcohol drinking were the only significant factors
affecting the incidence of diabetes between the two groups. There was no significant difference regarding sonar
findings although cirrhosis was more prevalent among diabetic HCV cases and the fibrosis score was higher in
diabetic HCV patients than among the non diabetic HCV cases.
Conclusion: The diabetic patients in the HCV group were older, more likely to have a history of alcohol drinking
than the non diabetic HCV cases. Age and alcohol drinking are factors that could potentially contribute to the
development of type 2 diabetes. Logistic regression analyses showed that age and residence in urban regions
were the predictive variables that could be associated with the presence of diabetes. Alcohol consumption was
not a significant predictive factor.
Background
The highest Hepatitis C Virus (HCV) prevalence in the
world occurs in Egypt at an estimated 12% among the
general population [1] and reaches 40% in persons 40
years of age and above in rural areas [2]. HCV Genotype
4 is the predominant genotype being isolated from up to
91% of HCV-infected persons in Egypt [3]. The origin of
the HCV epidemic in Egypt has been attributed to intra-
venous schistosomiasis treatment in rural areas in the
1960s-70s [4].
Although HCV targets at the liver, it has become
interestingly evident that HCV can induce diseases of
many organs. Cacoub et al. [5] reported that 38% of
patients with HCV would manifest at least one extrahe-
patic manifestation during the illness.
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infection include endocrinological manifestations such
as diabetes mellitus (DM) [6] and thyroiditis [7], rheu-
matologic manifestations such as arthralgias, arthritis [8]
and mixed cryoglobulinemia [9]. The prevalence of clini-
cally significant EH manifestations is relatively low, but
can be associated with significant morbidity and even
mortality. An awareness and recognition of these mani-
festations is of paramount importance in facilitating
early diagnosis and management of these complications
[10].
Type 2 diabetes (T2D) is a major public health pro-
b l e mw o r l d w i d e[ 1 1 ]a sp e o p l eb e c o m em o r eo b e s ea n d
live a more sedentary lifestyle [12]. This is in agreement
with studies on T2D in noninfected individuals as well
as patients infected with other HCV genotypes. The fol-
lowing risk factors are strongly associated with T2D:
family history, body fat distribution, age, sex, smoking,
and physical activity [13].
Several studies from different parts of the world have
found that 13% to 33% of patients with chronic HCV
have associated diabetes, mostly type II DM [14]. Dia-
betes was more frequent in patients having liver cirrho-
sis than those having chronic hepatitis [15]. Thus DM
appears to be a unique EH manifestation of chronic
HCV infection [16].
In Egypt the prevalence of DM was 25.4% among
HCV patients [17]. Chronic hepatitis C patients are
three times more likely to develop DM than HCV sero-
negative patients [17,14]. Therefore, it is important to
identify the magnitude of the problem of diabetes in
order to optimize the treatment of chronic hepatitis C.
The objective of this study was to evaluate the preva-
lence of DM and other EH manifestations among
patients with different HCV morbidity stages including
asymptomatic, chronic hepatic and cirrhotic patients age
and sex matched.
Patients and methods
Study design
The current research represents a case control study
where patients with chronic HCV infection attending
the outpatient clinic of Kasr El-Aini Hospital, Cairo
University (KAH), National Hepatology and Tropical
Medicine Research Institute (NHTMRI) and Viral Hepa-
titis Research Laboratory (VHRL) were interviewed.
Patients were subjected to a questionnaire to screen
those having EH manifestations and general examina-
tion. Patients were referred to rheumatologist, dermatol-
ogist for further assessment according to their clinical
complaints. Laboratory investigations included complete
blood picture, liver function tests and blood glucose.
Abbott AxSYM System HCV version 3.0 was used for
HCV Ab detection followed by In-house RT-PCR [18]
for confirmation. Liver function tests (LFT) were carried
out using Beckman Synchron CX4 Delta Clinical System
(U.S.A.). Serological assay included cryoglobulin profile,
rheumatoid factor, antinuclear antibody and HCV-PCR
to assess viral load. Abdominal ultrasonography and
biopsy was available from some of the patients.
Only HCV patients who were elder than 18 years and
had their antibody profile positive for HCV were
included as cases. Patients with decompensated liver dis-
ease, cancer, on interferon therapy, having end stage
renal disease or coexisting viral infection like hepatitis B
surface antigen positive patients, pregnant females were
excluded from the research. Controls were with normal
liver function tests, no serological evidence of HCV and
no recent illness.
Defining type 2 diabetes was done according to the
American Diabetes Association guidelines (2008)[19].
The current research was approved by the ethics com-
mittee of the NHTMRI. All patients gave informed writ-
ten consents prior to participation and the study was
conducted in accordance with Helsinki declaration.
Statistical Analysis
Comparisions between groups (cases and controls) were
done using the Student’s t test for continuous variables
and x
2 test was used for nominal categorical variables.
Continuous variables were summarized as mean ± SD
and categorical variables as frequency and percentage,
unless otherwise stated.
All analyses were performed with SPSS software for
Windows, version 13 (SPSS Inc., Chicago, IL). Correla-
tion was determined by Pearson’s linear regression ana-
lysis. All P values are based on a two-sided test of
statistical significance. P value of ≤ 0.05 will be consid-
ered as significant. Logistic regression analyses were
used to evaluate the predictive variables that could be
associated with the presence of diabetes.
Results
I-HCV cases
The mean age of cases (± Standard deviation) was 41.7
(± 10.6) with age range 19 to 65 years old (Table 1).
71.6% were males and 28.4% females. Over two-thirds
(68.2%) of cases were from urban regions with 45.7% of
them did not complete their secondary education.
Regarding their occupation, most of the study sample
were skilled workers (29.1%), employees (22.8%), house-
wives (20.4%), students (1.0%) and others (26.9%).21.4%
of them were current smokers, 5.2% were shisha smo-
kers and 7.0% drinked alcohol.
At least one EH manifestation was shown in 63.3% of
HCV cases. Cryoglobulinemia was found positive in 22
patients (7.6%). Rheumatologic manifestations were in
18.4% and dermatologic manifestations in 9.6% of the
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valent rheumatologic and dermatological manifestation
respectively.
II- Diabetes mellitus in chronic HCV cases
The mean age of HCV diabetic cases (± SD) [48.1 (±
9.2)] was statistically significantly higher than that of
HCV nondiabetics [40.7 (± 10.4)] (P value = 0.001).
Gender, level of education, marital status and occupa-
tion did not affect the incidence of diabetes among
HCV cases (P values = 0.90, 0.35, 0.13 and 0.46 respec-
tively). However, current res i d e n c ed i da f f e c tt h ei n c i -
dence of DM. 85% of diabetic HCV cases and 65.5% of
non diabetic HCV cases were from urban regions and
this difference was statistically significant. Regarding
special habits, diabetic HCV cases were more often
found to smoke shisha & drink alcohol than non dia-
betics (Table 2). However, they smoke less than nondia-
betic HCV cases. The difference was statistically
significant regarding alcohol drinking only.
Diabetic cases were more prone to have cirrhosis than
nondiabetic HCV cases. Also their stage of liver fibrosis
and inflammation was more severe than nondiabetic
HCV cases. However, the difference was not statistically
significant between diabetic and nondiabetic HCV cases
regarding liver condition. There was no significant dif-
ference between diabetic and non diabetic HCV cases
regarding the laboratory findings (Table 3).
III. Case control study. HCV cases and non HCV controls
The mean age of non diabetic HCV cases (± Standard
deviation) was 40.7 (± 10.4) with age range 19 to 65
years old which was less than the diabetic HCV cases.
Their mean age (± Standard deviation) was 48.1 (± 9.2)
with age range 29 to 65 years old. The mean age of non
diabetic controls (± Standard deviation) was 41.6 (±
11.9) with age range 21 to 65 years old. Diabetic
nonHCV controls were elder in age than non diabetic
controls (Table 4). Table 4 also shows that age distribu-
tion, gender, current residence, level of education, and
marital status differed significantly among HCV cases
and nonHCV controls regarding diabetic groups.
Table 1 Sociodemograhic characteristics and special
habits of chronic hepatitis C cases
Characteristic HCV cases
N = 289
No (%)
Age (years)
-Mean ± SD 41.7 ± 10.6
-Range 19-65
Gender
-Male 207 (71.6)
-Female 82 (28.4)
Residence
-Urban 197 (68.2)
-Rural 92 (31.8)
Level of education
-Less than secondary 132 (45.7)
-Secondary & more 157 (54.3)
Marital status
-Not married 63 (21.8)
-Married 226 (78.2)
Occupation
-Skilled workers* 84 (29.1)
-Employees 66 (22.8)
- Student 3 (1.0)
-Housewife 59 (20.4)
-Others 77 (26.6)
Cigarette Smoking 60 (21.4)
Shisha Smoking 15 (5.2)
Alcohol Drinking 5 (7.0)
* skilled workers include farmer, builder, industrial, trade workers.
Table 2 Sociodemograhic characteristics and special
habits of diabetic and nondiabetic HCV cases
Parameters HCV Cases Total
N = 289
P-
value
Non diabetic
(N = 249)
No (%)
Diabetic
(N = 40)
No (%)
Age (years)
-Mean ± SD 40.7 ± 10.4 48.1 ± 9.2 41.7 ± 10.6 0.001
-Range 19-65 29-65 19-65
Gender
-Male 178 (71.5) 29 (72.5) 207 (71.6) 0.90
-Female 71(28.5) 11(27.5) 82 (28.4)
Current residence
-Urban 163 (65.5) 34 (85.0) 197 (68.2) 0.01
-Rural 86 (34.5) 6 (15.0) 92 (31.8)
Level of education
-Less than secondary 111 (44.6) 21 (52.5) 132 (45.7) 0.35
-Secondary & more 138 (55.4) 19 (47.5) 157 (54.3)
Marital status
-Not married 58 (23.3) 5 (12.5) 63 (21.8) 0.13
-Married 191 (76.7) 35 (87.5) 226 (78.2)
Occupation
-skilled workers 77 (30.9) 7 (17.5) 84 (29.1)
-employee 56 (22.5) 10 (25.0) 66 (22.8)
- student 3 (1.2) 0 3 (1.0) 0.46
-housewife 46 (18.5) 13 (32.5) 59 (20.4)
-others 67 (26.9) 10(25.0) 77 (26.6)
Cigarette Smoking 53 (22.0) 7 (17.5) 60 (21.4) 0.64
Shisha Smoking 11 (4.6) 4 (10.5) 15 (5.2) 0.27
Alcohol Drinking 2 (0.8) 3 (7.9) 5 (7.0) 0.02
N.B. Skilled workers include (farmer, builder, industrial, trade work).
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(7.7%) patients were found to be diabetic while 638
(92.3%) were non diabetic (Table 5). The difference was
statistically significant (P = 0.0001). Diabetic cases repre-
sented 13.8% of the HCV cases while diabetic controls
represented 4.2% of the controls.
Abnormal high ALT, high ALKP and high BIL values
was more frequently shown among HCV diabetic cases
compared with HCV nondiabetic cases (Table 6). In
non HCV controls, diabetic subjects less frequently
showed high AST and ALT. The difference was statisti-
cally significant regarding the former parameters.
IV. HCV Diabetics and non HCV Diabetics
The mean age of diabetic HCV cases (± SD) was 48.1 (±
9.1) with age range 29 to 65 years old. More than one
Table 3 Laboratory findings of diabetic and nondiabetic
HCV cases
Laboratory findings HCV Cases P-value
Non diabetic
No (%)
Diabetic
No (%)
Abnormal Liver function
￿ High ALT 174 (76) 34 (89.5) 0.06
￿ High AST 170 (75. 2) 24 (64.9) 0.18
￿ High ALKP 21 (19.1) 5 (25) 0.76
￿ High BIL 31 (17.5) 8 (26.7) 0.24
Abnormal Hemogram
￿ Anemia 29 (14.6) 4 (12.1) 0.92
￿ Thrombocytopenia 44 (23.4) 13 (41.9) 0.07
￿ Leukopenia 48 (24.9) 9 (27.3) 0.99
￿ Neutropenia 60 (39.5) 9 (36.0) 0.74
￿ Lymphopenia 9 (5.5) 1(3.2) 0.91
Autoimmune markers
￿ Positive ANA 10 (11.8) 2 (11.1) 0.75
￿ Positive RF 79 (59.0) 13 (52.0) 0.67
High Alpha-Feto protein 21(21) 3(3) 1.00
High Blood GLUC 0 40 (100) 0.0001
High Glycosylated Hb 3 (60) 7 (58.33) 0.633
High TSH 3 (2.77) 0 0.811
Table 4 Sociodemograhic characteristics of diabetic and nondiabetic HCV cases and diabetic and nondiabetic nonHCV
controls
Parameters HCV Cases Controls P-value
Non diabetic
(N = 249)
No (%)*
Diabetic
(N = 40)
No (%)
Non diabetic
(N = 277)
No (%)*
Diabetic
(N = 12)
No (%)
Age (years)
-Mean ± SD 40.7 ± 10.4 48.1 ± 9.2 41.6 ± 11.9 48.6 ± 8.4 0.001
-Range 19-65 29-65 21-65 34-65
Age distribution
-18-30 52 (20.9) 2 (5.0) 65 (23.5) 0 0.0001
-31-40 68 (27.3) 7 (17.5) 75 (27.1) 2 (16.7)
-41-50 81 (32.5) 15 (37.5) 70 (25.3) 4 (33.3)
51-60 45 (18.1) 13 (32.5) 49 (17.7) 5 (41.7)
-above 60 3 (1.2) 3 (7.5) 18 (6.5) 1 (8.3)
Gender
-Male 178 (71.5) 29 (72.5) 154 (55.6) 2 (16.7) 0.0001
-Female 71 (28.5) 11 (27.5) 123 (44.4) 10 (83.3)
Current residence
-Urban 163 (65.5) 34 (85.0) 0 0 0.0001
-Rural 86 (34.5) 6 (15.0) 277 (100) 12 (100)
Level of education
-Less than secondary 111 (44.6) 21 (52.5) 177 (63.9) 12 (100) 0.0001
-Secondary & more 138 (55.4) 19 (47.5) 100 (36.1) 0
Marital status
-Not married 58 (23.3) 5 (12.5) 44 (15.9) 5 (41.7) 0.03
-Married 191 (76.7) 35 (87.5) 233(84. 1) 7 (58.3)
Table 5 Blood sugar status of case and control study
groups
Blood sugar status No of patients N° (%) Total P-value
Cases Controls
Diabetic 40 (13.8) 12 (4.2) 52 (7.7) 0.0001
Non diabetic 249 (86.2) 277(95.8) 526(92.3)
Total 289 (100) 289(100) 578 (100)
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and 7.5% only above 60 years old (Table 7). The mean
age of diabetic controls (± SD) was 48.6(± 8.4) with age
range 34 to 65 years old. Males represented 72.5% of
the diabetic HCV cases but only 16.7% of diabetic con-
trols. All of the controls were from rural areas while
only 15% of the cases were from rural areas. None of
the controls completed their secondary education while
47.5% of the cases did. Table 7 also shows that 87.5% of
cases and 58.3% of the controls were married. The dif-
ference was statistically significant regarding the former
parameters except the marital status.
Regarding abnormal lab characteristics, Table 8 shows
that HCV cases were more likely to have high ALT
(89.5%) and AST (64.9%) than non HCV controls (8.3%
each).
Discussion
Several strands of evidence have suggested a possible
link between HCV infection and an increased prevalence
of Type2D [20]. Based on case-control studies, the pre-
valence of DM had been reported in 21% to 50% (a
two- to ten-fold increase in prevalence) of patients with
chronic HCV infection, which was significantly higher
than that in the general population or among patients
with other forms of liver diseases [21]. This study
showed that 13.84% of the HCV patients were type 2
diabetics. These results are comparable to the results of
the findings reported by Petit et al. [22], Wang et al.
[23] and Veldt et al. [24]. Other authors reported higher
numbers of diabetics in their studies on HCV patients
as El-Zayadi et al. [17] & Lecube et al. [25]. They
reported prevalence of DM to be 20.9%-29% among
HCV patients. Prevalences ranging between 32.5% and
39.8% were reported by Zhao et al. [26] and Chehadeh
et al. [14]. Differences in the criteria employed in the
diagnosis of DM, source of controls, case definition,
sample size and underlying target population may
explain much of this observed variability among studies.
Diabetes was shown to be prevalent in 4.15% of the
controls who represent age-matched normal population.
This result (among controls) is 3-4 times less than what
was found in this study (among HCV cases), indicating
that HCV patients are a high risk population for DM. In
contrast, some studies provided evidence against
Table 6 Laboratory findings of HCV cases and controls
Parameter Cases Controls P-value
Non diabetic
No (%)*
Diabetic
No (%)
Non diabetic
No (%)*
Diabetic
No (%)
Abnormal Liver function
￿ High ALT 174 (76.0) 34 (89.5) 24 (8.9) 1 (8.3) 0.001
￿ High AST 170 (75.2) 24 (64.9) 15 (5.5) 1 (8.3) 0.001
￿ High ALKP 21(19.1) 5(25.0) 0 0 0.02
￿High BIL 31 (17.5) 8 (26.7) 0 0 0.01
High Blood GLUC 0 40 (100) 0 12 (100) 0.0001
Table 7 Sociodemograhic characteristics of diabetic HCV
cases and nonHCV diabetic controls
Parameters Diabetic HCV
cases
(N = 40)
N° (%)
Diabetic
Controls
(N = 12)
N° (%)*
P-
value
Age (years)
-Mean ± SD 48.1 ± 9.1 48.6 ± 8.4 0.001
-Range 29-65 34-65
Age distribution
-18-30 2 (5.0) 0 0.0001
-31-40 7 (17.5) 2 (16.7)
-41-50 15 (37.5) 4 (33.3)
51-60 13 (32.5) 5 (41.7)
-above 60 3 (7.5) 1 (8.3)
Gender
-Male 29 (72.5) 2 (16.7) 0.0001
-Female 11 (27.5) 10 (83.3)
Current residence
-Urban 34 (85.0) 0 0.0001
-Rural 6 (15.0) 12 (100)
Level of education
-Less than
secondary
21 (52.5) 12 (100) 0.008
-Secondary & more 19 (47.5) 0
Marital status
-Not married 5 (12.5) 5 (41.7) 0.07
-Married 35 (87.5) 7 (58.3)
Table 8 Abnormal Lab characteristics of diabetic cases
and diabetic controls
Parameters Diabetic HCV cases
N=4 0
N° (%)
Diabetic Controls
N=1 2
N° (%)*
P-value
High ALT 34 (89.5) 1 (8.3) 0.001
High AST 24 (64.9) 1 (8.3) 0.001
High Blood GLUC 40 (100) 12 (100) 0.0001
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The prevalence of diabetes in adults in Egypt ranged
from 5% in rural communities in the Nile delta to 10%
in lower socioeconomic areas of Cairo and over 20% in
higher socioeconomic areas in Cairo [28]. Similar results
were reported from Italy and India [29,30]. Higher pre-
valences of DM were reported from other authors
[6,26]. This may be attributed to differences in environ-
mental influences, genetic susceptibility and diets.
Sociodemographic characters and special habits of cases
and controls
It was noticed that the highest percentage of diabetes
(37.5%) was among age group from 41-50 years which
was similar to that reported by Wang et al. [23]. Con-
versely, others stated that older age was a potential risk
factor for development of DM in HCV patients [31]. It
is interesting to note that older age is associated with
more severe liver disease among HCV-infected patients
[32]. Studies from Italy and USA referred that HCV
increases the prevalence of DM independently of age
[33,34]. These findings have some important clinical and
public health implications. They imply that the younger
the persons with HCV infection, the greater the risk
that they will develop diabetes than will their age-group
counterparts without HCV infection. Therefore, screen-
ing for and prevention of diabetes in persons with HCV
infection could be started earlier than the suggested age
of ≥ 45 years for the general population [19], especially
for those with higher body mass index levels or with
other risk factors for diabetes. In addition, young adults
with diabetes in communities with a high prevalence of
HCV infection could be tested for an underlying HCV
infection.
The mean age for HCV DM+ was higher than the
mean age for HCV DM- subjects which is interestingly
similar to the findings of Giordanino and coworkers
[35]. These findings support the idea that the induction
of diabetes in HCV patients is progressive rather than
abrupt [14]. Other studies suggest that HCV interferes
with glucose metabolism independently of age [21,24].
Diabetes was more prevalent in females than in males.
Our findings are similar to that reported by Huang et al.
[ 3 1 ] .M a l e sm a yb em o r ef r e quently exposed to HCV
infection because they have more risk factors including
schistosomal infection, shaving beards, accidents, and
exposure to operations and blood transfusions [36].
Otherwise, women might be more likely to be associated
with HCV clearance and lower rates of HCV-RNA posi-
tivity [37]. However, there was no significant difference
between diabetic and non-diabetic cases regarding gen-
der which was similar to other studies [24,33]. Persons
with type 2 DM tended to have lower educational
attainment [38]. This is in concordance with our study.
Habitual smoking is a well-documented risk factor for
exacerbation of liver conditions, such as increased ala-
nine transferase levels and increased fibrosis that would
increase the likelihood of type 2 diabetes [39]. There
was a history of cigarette smoking among 42.2% of HCV
subjects which is similar to that reported by Eissa et al.
[36]. Our study revealed that HCV cases who were cur-
rent cigarette smokers were more likely to be diabetic
(17.5%) than current shisha or goza smokers (10.5%).
Cases who had a history of cigarette smoking (50%)
were more likely to be diabetic than those with history
of shisha smoking (16.4%). That was in concordance
with findings of Alavian et al. [40]. Yet smoking was not
a significant predicting factor for diabetes which was
similar to results of Wang et al. [23].
Hepatitis C and excessive alcohol consumption are not
likely to have an additive effect in relation to the risk of
having diabetes [23]. Only 24.6% of the HCV subjects in
this study had a history of drinking alcohol and 7.9%
were current alcoholics. Current alcohol drinking was a
significant risk factor for developing DM which was in
agreement with and Ryu et al. [41] findings.
Liver condition
Patients with HCV-related liver cirrhosis are associated
with a significantly higher prevalence of DM than those
cirrhotic patients with other etiologies [42]. This is on
line with our study. This study showed that 23.1% of
HCV cirrhotics were diabetic which was similar to the
findings of other authors [35]. Higher figures were
reported by Kwon et al. [43]. The discrepancies among
studies may be explained by severity of liver disease. In
another remarkable study, in which cirrhotic HCV
patients were carefully excluded, a third of them had
diabetes [44]. On excluding cirrhotic patients from the
HCV cases in this study, 12.5% of the cases had DM
which was 4 times the prevalence in the controls repre-
senting the normal Egyptian population. Of interest,
that was consistent with a study on a large cohort of
patients conducted by Lecube and coworkers [25].
Taken together these findings suggest that HCV infec-
tion is a more important predictor of glucose intoler-
ance than cirrhosis, and the combination of both factors
further increases the risk of diabetes. Other factors than
cirrhosis must be found to explain the increased preva-
lence of DM in HCV patients [22].
Regarding other sonographic features, anti-HCV-posi-
tive subjects with sonographic evidence of bright liver,
enlarged liver and chronic liver disease had a higher
prevalence of T2D compared with patients whose sono-
graphic features were normal. The trend of increasing
prevalence of T2D with severity of sonographic stages in
anti-HCV-positive subjects implies that viral inflamma-
tory activity, time duration, insulin secretion, insulin
sensitivity, and the interaction with other well-known
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the development of T2D.
Diabetes is associated with increased fibrosis in
chronic HCV but such an association may be related to
the high prevalence of diabetes in patients with cirrhosis
[45]. The frequency of diabetes mellitus increased along
with pathological staging [24]. The fibrosis score was
higher in diabetic HCV patients [15]. The results here-
after were on line with that. In this study, none of the
diabetic patients had normal stage of fibrosis. Nearly
one half of the diabetic patients (46.7%) showed moder-
ate to severe fibrosis compared to 34.7% in non diabetic
HCV patients. The discrepancies among studies may be
explained by differences in ethnic background, HCV
genotype frequency, and duration and severity of liver
disease.
Liver biopsy specimens of diabetic HCV patients
showed higher inflammatory activity defined by histolo-
gical activity index score than the nondiabetic HCV
group for moderate and severe stages. That is in line
with the results reported by several authors [46]. HCV
patients who develop diabetes had more severe liver dis-
ease according to both their liver enzymes and biopsy
findings [22]. These observations suggest that not HCV
infection itself but the resultant ongoing inflammation
of the liver might determine a higher risk for DM.
Patients with an earlier stage of chronic HCV infection
have b-cell dysfunction but diabetes does not become
established until cirrhosis has supervened [47]. This
could explain the negative association between stage of
inflammation (found to be normal) and DM manifest in
this series.
Blood picture did not differ between the 2 HCV
groups. This study was in keeping with the findings of
other authors [44]. There was at least one abnormal fea-
ture in the hemogram of 68.6% of the HCV cases.
Individuals with type 2 diabetes have a higher inci-
dence of liver function test (LFT) abnormalities than
individuals who do not have diabetes [48] which is simi-
lar to our findings. However, Chehadeh et al. [14] found
no difference in this aspect. Interestingly, diabetic con-
trols in this study had higher mean values of ALT than
nondiabetic controls. Studies on European diabetics
showed the same results in Greece [49] and Spain [25].
Conclusion
Despite the close relationship between HCV infection
and DM, The underlying mechanism(s) that links dia-
betes and HCV infection remains conjectural. The
increased prevalence of diabetes in chronic hepatitis is
unique to HCV and therefore that unique mechanisms
may underlie glucose intolerance in HCV patients. Type
2 DM is a complex, multisystem disease with a patho-
physiology that includes a defect in insulin secretion,
increased hepatic glucose production, and resistance to
the action of insulin, all of which contribute to the
development of overt hyperglycemia. In addition, obe-
sity, aging, and genetic factors such as family history of
DM all may contribute to the development of type 2
DM. All these factors make it difficult to evaluate the
pathogenic role of HCV infection in the development of
type 2 DM.
Our findings that a more severe inflammatory and
fibrotic process were associated with diabetes suggest
that the pathogenesis of DM in HCV infection may be
multifactorial- a precirrhotic state leading to an abnor-
mal glucose metabolism and insulin resistance, acting in
conjunction with undefined pancreatic damage, occur-
ring in genetically prone patients is an explanation.
Another possible explanation, as proposed by Caronia et
al [47], is that b-cell responsiveness is impaired in
patients with HCV, possibly because of direct viral
effects on b-cell function. Thus for a given degree of
liver dysfunction-and presumably IR, diabetes would be
more likely to occur in patients with HCV.
In our study, the diabetic patients in the HCV group
were older, more likely to have a history of alcohol
drinking than the non diabetic HCV cases, factors that
could potentially contribute to the development of type
2 diabetes. Logistic regression analyses showed that age
and residence in urban regions were the predictive vari-
ables that could be associated with the presence of dia-
betes. Alcohol consumption was not a significant factor.
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